Answers are grounded in this paper and cite their sources.
Glycoprotein IIb/IIIa inhibitors potently inhibit platelet aggregation by blocking the final common pathway, offering a strategy to prevent ischemic complications during percutaneous coronary revascularization.
Plaque rupture and vascular thrombosis are key initiating factors in the pathogenesis of ischemic complications of percutaneous coronary revascularization (1,2). The central role of platelet activity in this setting is highlighted by the unequivocal benefit of aspirin in preventing death or myocardial infarction among patients undergoing coronary intervention (3). Newer strategies for more potent inhibition of platelet activity at the injured coronary plaque focus on the integrin glycoprotein (GP) IIb/IIIa receptor on the platelet surface membrane, which binds circulating fibrinogen or von Willebrand factor and crosslinks adjacent platelets as the final common pathway to platelet aggregation (4). Pharmacologic compounds directed against GPIIb/IIIa block this receptor, prevent binding of circulating adhesion molecules, and potently inhibit platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Lincoff et al. (2003) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: